Vanguard Fiduciary Trust
ESLA icon

Vanguard Fiduciary Trust’s Estrella Immunopharma ESLA Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$67.5K Hold
64,921
– – ﹤0.01% 3805
2026
Q1 		$68.8K Buy
+64,921
New +$74.6K ﹤0.01% 3774

Other funds holding ESLA

AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Fiduciary Trust's ESLA Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Estrella Immunopharma (ESLA) position steady in Q2 2026 at 64,921 shares worth $67.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3805.

Vanguard Fiduciary Trust first reported a position in ESLA in Q1 2026 and has held it in 2 quarters since. The position peaked at $68.8K in Q1 2026. 15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

  • Vanguard Fiduciary Trust held 64,921 shares of Estrella Immunopharma worth $67.5K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Estrella Immunopharma share count unchanged in Q2 2026.
  • Estrella Immunopharma made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3805 holding.
  • Vanguard Fiduciary Trust first reported a position in Estrella Immunopharma in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Estrella Immunopharma position peaked at $68.8K in Q1 2026.
  • 15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.